DrugPatentWatch Database Preview
Encorafenib - Generic Drug Details
What are the generic sources for encorafenib and what is the scope of freedom to operate?
Encorafenib
is the generic ingredient in one branded drug marketed by Array Biopharma Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Encorafenib has one hundred and twenty-six patent family members in forty-eight countries.
One supplier is listed for this compound.
Summary for encorafenib
| International Patents: | 126 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 35 |
| Clinical Trials: | 21 |
| Patent Applications: | 71 |
| DailyMed Link: | encorafenib at DailyMed |
Recent Clinical Trials for encorafenib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bristol-Myers Squibb (BMS) | Phase 1/Phase 2 |
| EADO - European Association of Dermato Oncology | Phase 2 |
| University of California, San Francisco | Phase 1/Phase 2 |
Synonyms for encorafenib
| 1269440-17-6 |
| 8L7891MRB6 |
| A13226 |
| AC-30230 |
| AS-35201 |
| BCP08458 |
| BDBM221688 |
| Braftovi |
| Braftovi (TN) |
| Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester |
| CHEMBL3301612 |
| CMJCXYNUCSMDBY-ZDUSSCGKSA-N |
| CS-2289 |
| D11053 |
| DB11718 |
| DTXSID00155347 |
| Encorafenib (JAN/USAN/INN) |
| Encorafenib (LGX818) |
| Encorafenib [USAN:INN] |
| EX-A1587 |
| GTPL7908 |
| HY-15605 |
| LGX 818 |
| LGX-818 |
| LGX-818(Encorafenib) |
| LGX818 |
| Methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate |
| methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate |
| MFCD25976758 |
| NCGC00378599-03 |
| NVP-LGX818 |
| NVP-LGX818-NXA |
| s7108 |
| SB16926 |
| SCHEMBL8228295 |
| UNII-8L7891MRB6 |
| US9314464, 9 |
| ZINC68249103 |
US Patents and Regulatory Information for encorafenib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | DISCN | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for encorafenib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Croatia | P20140799 | Start Trial |
| Morocco | 35716 | Start Trial |
| Guatemala | 201200053 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for encorafenib
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2727918 | 2019C/509 | Belgium | Start Trial | PRODUCT NAME: COMBINAISON DE BINIMETINIB ET D'ENCORAFENIB, CHACUN SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/18/1315 ET EU/1/18/1314 20180924 |
| 2470526 | LUC00101 | Luxembourg | Start Trial | PRODUCT NAME: BRAFTOVI - ENCORAFENIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1314 20180924 |
| 2727918 | 122019000023 | Germany | Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
